

PRODUCT ORDERING GUIDE

Manufactured By	MorphoSys US Inc. - 844-MOR-1992						
Marketed By	MorphoSys US Inc. - www.MorphoSys-US.com Incyte Corporation - www.Incyte.com						
Product Name	MONJUVI						
Generic Name	tafasitamab-cxix						
Product Website	www.MONJUVIHCP.com						
Indication	<p>MONJUVI (tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).</p> <p>This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</p>						
Product Information	<p>NDC: 10-Digit - 73535-208-01 11-Digit - 73535-0208-01</p> <p>Payer requirements regarding use of a 10-digit or 11-digit NDC vary.</p> <p>Description: 200 mg single-dose vial as lyophilized powder for reconstitution for injection</p>						
Wholesale Acquisition Cost	\$1,200 / Vial as of August 2020						
Ordering MONJUVI	<p>All orders must be placed with one of the Specialty Distributors listed below:</p> <table border="0"> <tr> <td> <p>ASD Healthcare <i>AmerisourceBergen</i> 5025 Plano Parkway, Carrollton, TX 75010 Phone: 800-746-6273 Fax: 800-547-9413 ASD.CustomerService@asdhealthcare.com www.asdhealthcare.com MONJUVI Item # 58057</p> </td> <td> <p>Oncology Supply <i>AmerisourceBergen</i> 2801 Horace Shepard Drive, Dothan, AL 36303 Phone: 800-633-7555 CustServ@oncologysupply.com www.oncologysupply.com MONJUVI Item # 58057</p> </td> </tr> <tr> <td> <p>Cardinal Health Specialty Pharmaceutical Distribution 233 Mason Road, LaVergne, TN 37086 Phone: 855-855-0708 Phone: 877-453-3972 Fax: 877-274-9897 GMB-SPD-Specialty@cardinalhealth.com GMB-SPDOncologySalesTeam@cardinalhealth.com MONJUVI Item # 5653530</p> </td> <td> <p>CuraScript SD 255 Technology Park, Lake Mary, FL 32746 Phone: 877-599-7748 Fax: 800-862-6208 Customer.Service@curascript.com www.curascriptsd.com MONJUVI Item # 413402</p> </td> </tr> <tr> <td> <p>McKesson Plasma & Biologics 6535 N State Highway 161, Irving, TX 75039 Phone: 877-625-2566 Fax: 888-752-7276 MPBOrders@mckesson.com connect.mckesson.com MONJUVI Item # 1559434</p> </td> <td> <p>McKesson Specialty Care Distribution 6535 N State Highway 161, Irving, TX 75039 Phone: 800-482-6700 mcs.mckesson.com MONJUVI Item # 5010390</p> </td> </tr> </table> <p>For Specialty Pharmacy services, customers can contact:</p> <p>Biologics by McKesson 13000 Weston Parkway, Suite 105, Cary, NC 27513 Phone: 800-850-4306 Fax: 800-823-4506 Email: MyCareTeam@mckesson.com biologics.mckesson.com</p>	<p>ASD Healthcare <i>AmerisourceBergen</i> 5025 Plano Parkway, Carrollton, TX 75010 Phone: 800-746-6273 Fax: 800-547-9413 ASD.CustomerService@asdhealthcare.com www.asdhealthcare.com MONJUVI Item # 58057</p>	<p>Oncology Supply <i>AmerisourceBergen</i> 2801 Horace Shepard Drive, Dothan, AL 36303 Phone: 800-633-7555 CustServ@oncologysupply.com www.oncologysupply.com MONJUVI Item # 58057</p>	<p>Cardinal Health Specialty Pharmaceutical Distribution 233 Mason Road, LaVergne, TN 37086 Phone: 855-855-0708 Phone: 877-453-3972 Fax: 877-274-9897 GMB-SPD-Specialty@cardinalhealth.com GMB-SPDOncologySalesTeam@cardinalhealth.com MONJUVI Item # 5653530</p>	<p>CuraScript SD 255 Technology Park, Lake Mary, FL 32746 Phone: 877-599-7748 Fax: 800-862-6208 Customer.Service@curascript.com www.curascriptsd.com MONJUVI Item # 413402</p>	<p>McKesson Plasma & Biologics 6535 N State Highway 161, Irving, TX 75039 Phone: 877-625-2566 Fax: 888-752-7276 MPBOrders@mckesson.com connect.mckesson.com MONJUVI Item # 1559434</p>	<p>McKesson Specialty Care Distribution 6535 N State Highway 161, Irving, TX 75039 Phone: 800-482-6700 mcs.mckesson.com MONJUVI Item # 5010390</p>
<p>ASD Healthcare <i>AmerisourceBergen</i> 5025 Plano Parkway, Carrollton, TX 75010 Phone: 800-746-6273 Fax: 800-547-9413 ASD.CustomerService@asdhealthcare.com www.asdhealthcare.com MONJUVI Item # 58057</p>	<p>Oncology Supply <i>AmerisourceBergen</i> 2801 Horace Shepard Drive, Dothan, AL 36303 Phone: 800-633-7555 CustServ@oncologysupply.com www.oncologysupply.com MONJUVI Item # 58057</p>						
<p>Cardinal Health Specialty Pharmaceutical Distribution 233 Mason Road, LaVergne, TN 37086 Phone: 855-855-0708 Phone: 877-453-3972 Fax: 877-274-9897 GMB-SPD-Specialty@cardinalhealth.com GMB-SPDOncologySalesTeam@cardinalhealth.com MONJUVI Item # 5653530</p>	<p>CuraScript SD 255 Technology Park, Lake Mary, FL 32746 Phone: 877-599-7748 Fax: 800-862-6208 Customer.Service@curascript.com www.curascriptsd.com MONJUVI Item # 413402</p>						
<p>McKesson Plasma & Biologics 6535 N State Highway 161, Irving, TX 75039 Phone: 877-625-2566 Fax: 888-752-7276 MPBOrders@mckesson.com connect.mckesson.com MONJUVI Item # 1559434</p>	<p>McKesson Specialty Care Distribution 6535 N State Highway 161, Irving, TX 75039 Phone: 800-482-6700 mcs.mckesson.com MONJUVI Item # 5010390</p>						

Important Safety Information

Contraindications: None.

Warnings and Precautions:

- **Infusion-Related Reactions (IRRs).** MONJUVI can cause IRRs, including chills, flushing, dyspnea, and hypertension. Premedicate patients and monitor frequently during infusion. Based on the severity of the IRR, interrupt or discontinue MONJUVI and institute appropriate medical management.

Please see additional Important Safety Information on next page and full [Prescribing Information](#).

Dispensing Pack Dimensions	Depth: 33.5 mm	Height: 76 mm	Width: 37.5 mm
How Supplied	MONJUVI® (tafasitamab-cxix) for injection is a sterile, preservative-free, white to slightly yellowish lyophilized powder for reconstitution supplied as a 200 mg single-dose vial. Each 200 mg vial is individually packaged in a carton.		
Storage and Handling	<p>Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not shake. Do not freeze.</p> <p>If needed, store the reconstituted solution in the vial for a maximum of 12 hours either refrigerated at 36°F to 46°F (2°C to 8°C) or room temperature at 68°F to 77°F (20°C to 25°C) before dilution. Protect from light during storage. Do not freeze or shake.</p> <p>If not used immediately, store the diluted MONJUVI infusion solution refrigerated for up to 18 hours at 36°F to 46°F (2°C to 8°C) and/or at room temperature for up to 12 hours at 68°F to 77°F (20°C to 25°C). The room temperature storage includes time for infusion. Protect from light during storage. Do not freeze or shake.</p> <p>MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions (IRRs).</p> <p>Please see full Prescribing Information for detailed preparation and administration including reconstitution information.</p>		
Packaging	Sales Unit: One single-dose vial	Units Per Case: One vial per carton	
Product Expiration	Expiration date printed on both single-dose vial and carton		
Product Returns	<p>Credit for returns is subject to MorphoSys' current Return Goods Policy</p> <p>Please contact ICS for more information: Phone - 866-765-0919 Email - MorphoSysReturns@icsconnect.com</p>		
Product Information	<p>MorphoSys Medical Information Phone - 844-667-1992 Email - MedInfo@MorphoSys.com</p>		
Reimbursement and Patient Support	<p>My MISSION Support Phone - 855-421-6172 Web - www.MyMISSIONSupport.com</p>		

Important Safety Information *(continued)*

Warnings and Precautions *(continued)*:

- **Myelosuppression.** MONJUVI can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Monitor complete blood counts (CBC) prior to administration of each treatment cycle and throughout treatment. Monitor patients with neutropenia for signs of infection. Consider granulocyte colony-stimulating factor administration. Withhold MONJUVI based on the severity of the adverse reaction. Refer to the lenalidomide prescribing information for dosage modifications.
- **Infections.** Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with MONJUVI and following the last dose. 73% of the 81 patients developed an infection. The most frequent infections were respiratory tract infection, urinary tract infection, bronchitis, nasopharyngitis and pneumonia. Grade 3 or higher infection occurred (30% of 81 patients). The most frequent grade 3 or higher infection was pneumonia. Infection-related deaths were reported (2.5% of 81 patients). Monitor patients for signs and symptoms of infection and manage infections as appropriate.
- **Embryo-Fetal Toxicity.** Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus and women of reproductive potential to use effective contraception during treatment with MONJUVI and for at least 3 months after the last dose. The combination of MONJUVI with lenalidomide is contraindicated in pregnant women. Refer to the lenalidomide prescribing information on use during pregnancy.

Adverse Reactions: The most common adverse reactions (≥20%) were neutropenia (51%), fatigue (38%), anemia (36%), diarrhea (36%), thrombocytopenia (31%), cough (26%), pyrexia (24%), peripheral edema (24%), respiratory tract infection (24%), and decreased appetite (22%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.

Please see the full [Prescribing Information](#) for additional Important Safety Information.